Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world.
Pasini F, Barile C, Caruso D, Modena Y, Fraccon AP, Bertolaso L, Menon D, La Russa F, Crepaldi G, Bononi A, Spezzano R, Padrini R, Corona G, Gusella M. Pasini F, et al. Invest New Drugs. 2018 Oct;36(5):927-932. doi: 10.1007/s10637-018-0631-8. Epub 2018 Jun 28. Invest New Drugs. 2018. PMID: 29956056 Clinical Trial.
Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
Gusella M, Pasini F, Caruso D, Barile C, Modena Y, Fraccon AP, Bertolaso L, Menon D, Crepaldi G, Bononi A, Spezzano R, Telatin GA, Corona G, Padrini R. Gusella M, et al. Among authors: pasini f. Cancer Chemother Pharmacol. 2019 Mar;83(3):493-500. doi: 10.1007/s00280-018-3751-0. Epub 2018 Dec 12. Cancer Chemother Pharmacol. 2019. PMID: 30542768
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
Platania M, Pasini F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vattemi E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, Proto C, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, Lo Russo G, Tuzi A, Gallucci R, Cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F. Platania M, et al. Among authors: pasini f. Lung Cancer. 2019 Jun;132:17-23. doi: 10.1016/j.lungcan.2019.04.001. Epub 2019 Apr 3. Lung Cancer. 2019. PMID: 31097088 Clinical Trial.
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old.
Gusella M, Bononi A, Modena Y, Bertolaso L, Franceschetti P, Menon D, Pezzolo E, Barile C, Crepaldi G, Bolzonella C, Inno A, Padrini R, Pasini F. Gusella M, et al. Among authors: pasini f. Cancer Chemother Pharmacol. 2014 Mar;73(3):517-24. doi: 10.1007/s00280-014-2378-z. Epub 2014 Jan 18. Cancer Chemother Pharmacol. 2014. PMID: 24442033 Clinical Trial.
Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?
Gusella M, Pasini F, Corso B, Bertolaso L, De Rosa G, Falci C, Modena Y, Barile C, Da Corte Z D, Fraccon A, Toso S, Cretella E, Brunello A, Modonesi C, Segati R, Oliani C, Minicuci N, Padrini R; Italian TAM Group. Gusella M, et al. Among authors: pasini f. Pharmacol Res Perspect. 2020 Oct;8(5):e00646. doi: 10.1002/prp2.646. Pharmacol Res Perspect. 2020. PMID: 32813313 Free PMC article.
293 results